skip to main content
Idioma:
Resultados 1 2 3 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Elsevier ScienceDirect Journals remover tipo de recurso: Anais de Congresso remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
BENEFIT ASSESSMENT OF NEW METASTATIC BREAST CANCER (MBC) TREATMENTS – A MULTI-STAKEHOLDER APPROACH
BENEFIT ASSESSMENT OF NEW METASTATIC BREAST CANCER (MBC) TREATMENTS – A MULTI-STAKEHOLDER APPROACH
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

BENEFIT ASSESSMENT OF NEW METASTATIC BREAST CANCER (MBC) TREATMENTS – A MULTI-STAKEHOLDER APPROACH

Gordon, Jenn ; Bernardini, Benato ; Biganzoli, Laura ; Cardoso, Fatima ; Espin, Jaime ; Miikkulainen, Kaisa ; Spence, Danielle ; Schuurman, Susanne ; Spitz, Sabine ; Wilking, Nils ; Zernik, Nicole ; Ujupan, Sonia

BREAST, 2019, Vol.48, p.S34 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

Kummel, S ; Schmid, P ; Harbeck, N ; Takahashi, M ; Untch, M ; Boileau, JF ; Cortes, J ; McArthur, H ; Dent, R ; O'Shaughnessy, J ; Pusztai, L ; Foukakis, T ; Park, YH ; Hui, R ; Cardoso, F ; Denkert, C ; Zhu, Y ; Pan, W ; Karantza, V ; Fasching, P

BREAST, 2023, Vol.68, p.S63 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study

Schmid, P ; Cortes, J ; Dent, RA ; Pusztai, L ; McArthur, HL ; Kummel, S ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Foukakis, T ; Reynier, MAM ; Ferreira, MIR ; Im, SA ; Cardoso, F ; Ding, Y ; Pan, W ; Tryfonidis, KE ; O'Shaughnessy, J

ANNALS OF ONCOLOGY, 2023, Vol.34, p.S1257 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Development of a patient-centered core outcome set for metastatic breast cancer
Development of a patient-centered core outcome set for metastatic breast cancer
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Development of a patient-centered core outcome set for metastatic breast cancer

de Ligt, KM ; de Rooij, BH ; Hedayati, E ; Karsten, MM ; Smaardijk, VR ; Velting, M ; Saunders, C ; Travado, L ; Cardoso, F ; Ramirez, EL ; Carney, NC ; Wengstrom, Y ; Ives, A ; Velikova, G ; Fialho, MDLS ; Koppert, L ; Van de Poll-Franse, LV

ANNALS OF ONCOLOGY, 2022, Vol.33, p.S213 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

Dent, RA ; Cortes, J ; Pusztai, L ; McArthur, HL ; Kuemmel, S ; Bergh, J ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Untch, M ; Fasching, PA ; Cardoso, F ; Haiderali, A ; Jia, L ; Nguyen, AM ; Pan, W ; O'Shaughnessy, J ; Schmid, P

ANNALS OF ONCOLOGY, 2022, Vol.33 (7), p.S600 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC

Schmid, P ; Cortes, J ; Dent, R ; Pusztai, L ; McArthur, H ; Kummel, S ; Bergh, J ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Untch, M ; Fasching, PA ; Cardoso, F ; Ding, Y ; Tryfonidis, K ; Aktan, G ; Karantza, V ; O'Shaughnessy, J

ANNALS OF ONCOLOGY, 2021, Vol.32 (9), p.1198 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)

Dent, R ; Cortes, J ; Pusztai, L ; McArthur, HL ; Kuemmel, S ; Bergh, J ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Foukakis, T ; Fasching, PA ; Cardoso, F ; Jia, L ; Jensen, E ; Karantza, V ; Aktan, G ; O'Shaughnessy, J ; Schmid, P

ANNALS OF ONCOLOGY, 2020, Vol.31, p.S1241 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Schmid, P ; Cortes, J ; Dent, R ; Pusztai, L ; McArthur, HL ; Kuemmel, S ; Bergh, J ; Denkert, C ; Park, YH ; Hui, R ; Harbeck, N ; Takahashi, M ; Foukakis, T ; Fasching, PA ; Cardoso, F ; Jia, L ; Karantza, V ; Zhao, J ; Aktan, G ; O'Shaughnessy, J

ANNALS OF ONCOLOGY, 2019, Vol.30, p.853 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS
MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS

Musoro, ZJ ; Coens, C ; Fiteni, F ; Pogoda, K ; Cardoso, F ; Tribius, S ; Singer, S ; Oosting, S ; Russell, N ; Simon, C ; Jean-Pascal, M ; Gregoire, V ; Velikova, G ; King, MT ; Gronvold, M ; Cocks, K ; Sprangers, M ; Eggermont, A ; Brandberg, Y ; Bottomley, A

VALUE IN HEALTH, 2018, Vol.21, p.S78 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
GMR sensors and magnetic nanoparticles for immuno-chromatographic assays
GMR sensors and magnetic nanoparticles for immuno-chromatographic assays
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

GMR sensors and magnetic nanoparticles for immuno-chromatographic assays

MARQUINA, C ; DE TERESA, J. M ; SERRATE, D ; MARZO, J ; CARDOSO, F. A ; SAUREL, D ; CARDOSO, S ; FREITAS, P. P ; IBARRA, M. R

Journal of magnetism and magnetic materials, 2012, Vol.324 (21), p.3495-3498 [Periódico revisado por pares]

Amsterdam: Elsevier

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (26)
  2. Revistas revisadas por pares (26)

Data de Publicação 

De até
Refinar
  1. Antes de2001  (4)
  2. 2001Até2003  (6)
  3. 2004Até2009  (4)
  4. 2010Até2019  (6)
  5. Após 2019  (8)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (25)
  2. Português  (1)
  3. Russo  (1)
  4. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.